ClinicalTrials.gg
TerminatedNCT04044690RECLAIIMUpdated Dec 9, 2025Results posted

A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of IgPro20 in Adults With Dermatomyositis (DM)

A Phase 3 interventional study of human immunoglobulin G and Placebo in Dermatomyositis, sponsored by CSL Behring. Terminated at 76 sites in 14 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-12-09.

Sponsored by CSL Behring (part of CSL Limited) · Phase 3, Interventional, and Treatment

Why this study was terminated
Primary endpoint not attained

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
134
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 94 studies in Dermatomyositis with a site in United States — 30 open to participants now, 33 under way, 6 of them phase 3. Dermatomyositis · United States.

Enrollment
15th of 73
134 · median 25
Started
2019
with 2 others
Phase 3
9 of 94
4 open now
Registered
52nd of 94
by date

Among the 94 studies in Dermatomyositis with a site in United States, this one is the 15th largest by enrollment of the 73 interventional ones that give a count, is one of 3 that started in 2019, is one of 9 in phase 3, and was the 52nd registered.

Dermatomyositis

184 studies on the registry are indexed under Dermatomyositis; 63 are open to participants now.

Browse Dermatomyositis studies →

Open to participants now

30 of the 94 studies in Dermatomyositis with a site in United States are open now. Recruiting first, the newest first:

25 more — sign in →

All 30 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 50 Dermatomyositis studies recruiting now, 24 (48%) set no upper age limit and 16 (32%) stop at 75 or younger; 15 take children under 18; 6 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 94 studies in Dermatomyositis with a site in United States, or all of them as a file.
02

Study summary

This is a phase 3, multicenter, randomized, placebo-controlled, double-blind study of IgPro20 (subcutaneous Ig) treatment in adult subjects with dermatomyositis (DM). The primary objective of this study is to assess the efficacy of IgPro20 subcutaneous (SC) doses in comparison to placebo in adult subjects with DM, as measured by responder status based on Total Improvement Score (TIS) assessments.

03

Conditions studied

  • Dermatomyositis

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female subjects ≥ 18 years of age
  • Diagnosis of at least probable idiopathic inflammatory myopathies (IIM) per European League Against Rheumatism/American College of Rheumatology (EULAR/ACR) Classification Criteria which includes confirmation of dermatomyositis (DM) rash/manifestation, disease activity defined by presence of DM rash / manifestation or an objective disease activity measure
  • Disease severity defined by Physician global activity visual analog scale (VAS) with a minimum value of 2.0 cm on a 10 cm scale and MMT-8 ≤ 142 or CDASI total activity score ≥ 14.
  • daily dose less than that or equal to 20 mg prednisolone equivalent

Exclusion criteria

Exclusion Criteria:

  • Cancer-associated myositis
  • Evidence of active malignant disease or diagnosed within the previous 5 years
  • Physician Global Damage score ≥ 3, or improvement between Screening Visit and Baseline
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
134 participants (actual)

Study arms

  • Experimental
    IgPro20

    human immunoglobulin G administered subcutaneously

    Drug: human immunoglobulin G

  • Placebo comparator
    Placebo

    human albumin solution administered subcutaneously

    Drug: Placebo

Interventions

  • human immunoglobulin G administered subcutaneously

    Also known as: IgPro20, Hizentra

  • DrugPlacebo

    contains 2% human albumin, similar excipients as IgPro20 (Hizentra), same volume, same duration, administered subcutaneously

06

What researchers measure

Primary outcomes

  1. Responder Rate

    A responder was defined as a participant with a TIS \>= 20 points at Week 25 and at least 1 of the previous scheduled visits (Week 17 or 21), who completes 24 weeks of randomized IMP treatment without the use of rescue corticosteroid treatment. The TIS was a sum response criterion which incorporates 6 weighted international myositis assessment and clinical studies (IMACS) core set measures (CSMs) including Physician and Patient Global Disease Activity (PGA), Manual Muscle Testing-8 (MMT-8), Health Assessment Questionnaire, Muscle Enzyme, and Extramuscular Global Activity (EGA). Thresholds for minimal, moderate, and major improvement were \>= 20, \>= 40, and \>= 60 points, respectively on the TIS. Percentage of responders at Week 25 based on TIS are reported here. Multiple imputation (MI) was used to impute missing values for participants who discontinued due to the military activities in Ukraine.

    Time frame: At Week 25

Secondary outcomes

  1. Mean TIS

    The TIS was a sum response criterion which incorporates 6 weighted IMACS CSMs including Physician and PGA, MMT-8, Health Assessment Questionnaire, Muscle Enzyme, and EGA. A total improvement score (range 0 to 100; higher the score, better the condition), determined by summing scores for each CSM, was based on improvement in and relative weight of each CSM. Thresholds for minimal, moderate, and major improvement were \>= 20, \>= 40, and \>= 60 points, respectively on the TIS. Least squares (LS) means were estimated using a mixed model repeated measures (MMRM) including treatment, visit, the interaction between treatment and visit, region, and baseline MMT-8 (\<=142 points vs \>142 points) as fixed effects, participant as a random effect.

    Time frame: At Week 25

  2. Mean Changes From Baseline in MMT-8

    The MMT-8 was a set of 8 designated muscles which were tested bilaterally (potential score ranging from 0 to 150): 7 biaxial muscles with a potential score 0 to 140 and 1 axial (neck flexors) with a potential score of 0 to 10. Improvement is documented with an increase in score. LS means were estimated using a MMRM including treatment, visit, the interaction between treatment and visit, and region as fixed effects, baseline MMT-8 as a continuous covariate and participant as a random effect.

    Time frame: From Baseline to Week 25

  3. Mean Changes From Baseline in Cutaneous Dermatomyositis Disease Area and Severity Index Total Activity Score (CDASI-A)

    The CDASI in its modified version 2 (V2) is a validated tool of skin disease activity (3 items) and damage (3 items) assessment. Scores range from 0-100 for activity and from 0-32 for damage. Improvement is documented with a decrease in score. LS means were estimated using a MMRM including treatment, visit, the interaction between treatment and visit, region, and baseline MMT-8 (\<=142 points vs \>142 points) as fixed effects, baseline CDASI-A as a continuous covariate, and participants as a random effect.

    Time frame: From Baseline to Week 25

  4. Percentage of Participants Who Are Able to Reduce the Oral Corticosteroid Dose by >= 25%

    Reduction in corticosteroid dose.

    Time frame: At Week 25

  5. Period 1: Mean TIS at Each Visit

    The TIS was a sum response criterion which incorporates 6 weighted IMACS CSMs including Physician and PGA, MMT-8, Health Assessment Questionnaire, Muscle Enzyme, and EGA. A total improvement score (range 0 to 100), determined by summing scores for each CSM, was based on improvement in and relative weight of each CSM. Thresholds for minimal, moderate, and major improvement were \>= 20, \>= 40, and \>= 60 points on the TIS.

    Time frame: At Week 5, 9, 13, 17, 21, and 25

  6. Period 2: Mean TIS at Each Visit

    The TIS was a sum response criterion which incorporates 6 weighted IMACS CSMs including Physician and PGA, MMT-8, Health Assessment Questionnaire, Muscle Enzyme, and EGA. A total improvement score (range 0 to 100), determined by summing scores for each CSM, was based on improvement in and relative weight of each CSM. Thresholds for minimal, moderate, and major improvement were \>= 20, \>= 40, and \>= 60 points on the TIS.

    Time frame: Week 25, 29, 33, 37, 41, 45, 49, and 53

  7. Period 1: Percentage of Participants Achieving TIS ≥ 20, ≥ 40 and ≥ 60 Points

    Participants were considered and reported in more than one category (TIS \>= 20, \>= 40 and \>= 60 Points).

    Time frame: At Week 5, 9, 13, 17, 21, and 25

  8. Period 2: Percentage of Participants Achieving TIS ≥ 20, ≥ 40 and ≥ 60 Points

    Participants were considered and reported in more than one category (TIS \>= 20, \>= 40 and \>= 60 Points).

    Time frame: Week 25, 29, 33, 37, 41, 45, 49, and 53

  9. Period 1: Time to First Achieving TIS >= 20, >= 40, and >= 60 Points on the TIS

    The observation was censored if no improvement was observed before the intake of rescue/increased doses of oral corticosteroids in SP1 or before the end of the period.

    Time frame: Up to Week 25

  10. Period 1 and 2: Time to First Achieving TIS >= 20, >= 40, and >= 60 Points Improvement on the TIS

    The observation was censored if no improvement was observed before the intake of rescue/increased doses of oral corticosteroids in SP1 or before the end of the period.

    Time frame: Up to Week 53

  11. Mean Changes From Baseline in Individual CSMs (Except Muscle Enzymes) and CDASI

    Individual CSMs included following: Myositis Disease Activity Assessment Tool (MDAAT) Physician global disease activity (PGDA), PGA assessment, MMT-8, health assessment questionnaire-disability index (HAQ-DI), and MDAAT-EGA. Higher values were associated with a better state of health for the MMT-8 (range 0 -150) assessment, while lower values were associated with a better state of health for: MDAAT-PGDA (range 0 -100), PGA (range 0-100), HAQ-DI (range 0-3), MDAAT-EGA (range 0 -100), and CDASI-A (range 0-100).

    Time frame: From Baseline to Week 25

  12. Mean Changes From Week 25 in Individual CSMs (Except Muscle Enzymes) and CDASI

    Individual CSMs included following: MDAAT-PGDA, PGA assessment, MMT-8, HAQ-DI, and MDAAT extramacular global assessment. Higher values were associated with a better state of health for the MMT-8 (range 0 -150) assessment, while lower values were associated with a better state of health for: MDAAT-PGDA (range 0 -100), PGA (range 0-100), HAQ-DI (range 0-3), MDAAT-EGA (range 0 -100), and CDASI-A (range 0-100).

    Time frame: From Week 25 to Week 53

  13. Period 1: Number of Participants Meeting Definition of Worsening (DOW) at Least Once, Twice, or > Twice

    The DOW consists of meeting 1 of the following criteria on 2 consecutive visits at least 2 weeks apart: PGA Assessment Visual Analog Scale (VAS) worsening \>= 2 cm\* and MMT-8 worsening \>= absolute 10%, or EGA worsening \>= 2 cm on the MDAAT VAS, or Any 3 of 6 CSM worsening by \>= absolute 20%. (\*If baseline PGA VAS is 8 to 10, then any worsening on Physician Global VAS was acceptable as long as MMT-8 criterion was met.)

    Time frame: Up to Week 25

  14. Period 1: Percentage of Participants Meeting DOW at Least Once, Twice, or > Twice

    The DOW consists of meeting 1 of the following criteria on 2 consecutive visits at least 2 weeks apart: PGA Assessment VAS worsening \>= 2 cm\* and MMT-8 worsening \>= absolute 10%, or EGA worsening \>= 2 cm on the MDAAT VAS, or Any 3 of 6 CSM worsening by \>= absolute 20%. (\*If baseline PGA VAS is 8 to 10, then any worsening on Physician Global VAS was acceptable as long as MMT-8 criterion was met.)

    Time frame: Up to Week 25

  15. Period 2: Number of Participants Meeting DOW at Least Once, Twice, or > Twice

    The DOW consists of meeting 1 of the following criteria on 2 consecutive visits at least 2 weeks apart: PGA Assessment VAS worsening \>= 2 cm\* and MMT-8 worsening \>= absolute 10%, or EGA worsening \>= 2 cm on the MDAAT VAS, or Any 3 of 6 CSM worsening by \>= absolute 20%. (\*If baseline PGA VAS is 8 to 10, then any worsening on Physician Global VAS was acceptable as long as MMT-8 criterion was met.)

    Time frame: From Week 25 up to Week 53

  16. Period 2: Percentage of Participants Meeting DOW at Least Once, Twice, or > Twice

    The DOW consists of meeting 1 of the following criteria on 2 consecutive visits at least 2 weeks apart: PGA Assessment VAS worsening \>= 2 cm\* and MMT-8 worsening \>= absolute 10%, or EGA worsening \>= 2 cm on the MDAAT VAS, or Any 3 of 6 CSM worsening by \>= absolute 20%. (\*If baseline PGA VAS is 8 to 10, then any worsening on Physician Global VAS was acceptable as long as MMT-8 criterion was met.)

    Time frame: From Week 25 up to Week 53

  17. Time to Meeting DOW for the First Time

    The DOW consists of meeting 1 of the following criteria on 2 consecutive visits at least 2 weeks apart: PGA Assessment VAS worsening \>= 2 cm\* and MMT-8 worsening \>= absolute 10%, or EGA worsening \>= 2 cm on the MDAAT VAS, or Any 3 of 6 CSM worsening by \>= absolute 20%. (\*If baseline PGA VAS is 8 to 10, then any worsening on Physician Global VAS was acceptable as long as MMT-8 criterion was met.) The observation was censored if no DOW was observed before the intake of rescue treatment or before the end of the period.

    Time frame: Up to Week 53

  18. Number of Participants Meeting DOW and Receiving Rescue Steroid Treatment

    The DOW consists of meeting 1 of the following criteria on 2 consecutive visits at least 2 weeks apart: PGA Assessment VAS worsening \>= 2 cm\* and MMT-8 worsening \>= absolute 10%, or EGA worsening \>= 2 cm on the MDAAT VAS, or Any 3 of 6 CSM worsening by \>= absolute 20%. (\*If baseline PGA VAS is 8 to 10, then any worsening on Physician Global VAS was acceptable as long as MMT-8 criterion was met.) The Number of participants meeting DOW and who received rescue steroid treatment are reported here.

    Time frame: Up to Week 25

  19. Percentage of Participants Meeting DOW and Receiving Rescue Steroid Treatment

    The DOW consists of meeting 1 of the following criteria on 2 consecutive visits at least 2 weeks apart: PGA Assessment VAS worsening \>= 2 cm\* and MMT-8 worsening \>= absolute 10%, or EGA worsening \>= 2 cm on the MDAAT VAS, or Any 3 of 6 CSM worsening by \>= absolute 20%. (\*If baseline PGA VAS is 8 to 10, then any worsening on Physician Global VAS was acceptable as long as MMT-8 criterion was met.) The percentage of participants meeting DOW and who received rescue steroid treatment are reported here.

    Time frame: Up to Week 25

  20. Number of Participants Who Start Oral Corticosteroid Dose Taper

    Time frame: Up to Week 25

  21. Percentage of Participants Who Start Oral Corticosteroid Dose Taper

    Time frame: Up to Week 25

  22. Number of Participants Who Are Able to Reduce the Oral Corticosteroid Dose by >= 25%, >= 50%, >= 75%

    Time frame: Up to Week 25 and 52

  23. Percentage of Participants Who Are Able to Reduce the Oral Corticosteroid Dose by >= 25%, >= 50%, >= 75%

    Time frame: Up to Week 25 and 52

  24. Percentage of Participants Receiving Rescue Corticosteroid Treatment

    Time frame: Up to Week 25

  25. Percentage of Participants Whose Rescue Corticosteroid Treatment is Tapered

    Time frame: Up to Week 25

  26. Time to First Intake of Rescue Corticosteroid Treatment

    The observation was censored if no Rescue was observed before the last day of the last week with IMP intake or before the end of the period.

    Time frame: Up to Week 25

  27. Number of Participants Having at Least 1 Level, 2 Levels, and More Than 2 Levels of Improvement From Baseline in Mobility, Self-care, and Usual Activities Domains of EuroQoL 5-Dimension Questionnaire (EQ-5D-5L)

    EQ-5D-5L was assessed across 5 levels, with participants selecting the option that best described their health on that day, ranging from "no problems" to "unable to" walk, wash/dress, or perform usual activities. Out of total participants of each arm, only participants having at least 1 Level, 2 Levels, and more than 2 Levels of improvement from baseline in Mobility, Self-care, and Usual Activities Domains of EQ-5D-5L are reported in this outcome measure.

    Time frame: From Baseline to Week 13 and 25

  28. Percentage of Participants Having at Least 1 Level, 2 Levels, and More Than 2 Levels of Improvement From Baseline in Mobility, Self-care, and Usual Activities Domains of EQ-5D-5L

    EQ-5D-5L was assessed across 5 levels, with participants selecting the option that best described their health on that day, ranging from "no problems" to "unable to" walk, wash/dress, or perform usual activities. Out of total participants of each arm, only participants having at least 1 Level, 2 Levels, and more than 2 Levels of improvement from baseline in Mobility, Self-care, and Usual Activities Domains of EQ-5D-5L are reported in this outcome measure.

    Time frame: From Baseline to Week 13 and 25

  29. Number of Participants Having no Reduction in Levels, at Least 1 Level, 2 Levels, and More Than 2 Levels of Improvement From Week 25 in Mobility, Self-care, and Usual Activities Domains of EQ-5D-5L

    EQ-5D-5L was assessed across 5 levels, with participants selecting the option that best described their health on that day, ranging from "no problems" to "unable to" walk, wash/dress, or perform usual activities. Out of total participants of each arm, only participants having no reduction, at least 1 Level, 2 Levels, and more than 2 Levels of improvement from baseline in Mobility, Self-care, and Usual Activities Domains of EQ-5D-5L are reported in this outcome measure.

    Time frame: From Week 25 to 41 and 53

  30. Percentage of Participants Having no Reduction in Levels, at Least 1 Level, 2 Levels, and More Than 2 Levels of Improvement From Week 25 in Mobility, Self-care, and Usual Activities Domains of EQ-5D-5L

    EQ-5D-5L was assessed across 5 levels, with participants selecting the option that best described their health on that day, ranging from "no problems" to "unable to" walk, wash/dress, or perform usual activities. Out of total participants of each arm, only participants having no reduction, at least 1 Level, 2 Levels, and more than 2 Levels of improvement from baseline in Mobility, Self-care, and Usual Activities Domains of EQ-5D-5L are reported in this outcome measure.

    Time frame: From Week 25 to 41 and 53

  31. Percentage of Participants With Treatment Emergent Adverse Events (TEAEs), Related TEAEs and Serious TEAEs

    Time frame: Up to 5 years

  32. Annualized Rate of TEAEs, Related TEAEs and Serious TEAEs Per Time at Risk

    Time frame: Up to 5 years

  33. Annualized Rate of Mild, Moderate, and Severe TEAEs Per Time at Risk

    Time frame: Up to 5 years

07

Results

Posted Dec 9, 2025
Limitations and caveats
A Good Clinical Practice (GCP) breach was identified and reported to regulatory authorities regarding insufficient safety information provided by one site for one Suspected Unexpected Serious Adverse Reaction (SUSAR) and one Adverse Event of Special Interest (AESI). The sponsor made repeated requests to obtain verification of the data, which the site did not provide. This limitation may have impacted the completeness of safety data characterization for these specific events.

Participant flow

This study was conducted from 21 October 2019 to 02 December 2024.

Period 1
Participant flow — Period 1
MilestoneSequence A: IgPro20 / IgPro20 / IgPro20Sequence B: Placebo / IgPro20 / IgPro20
Started6767
Treated6767
Completed5655
Not completed1112
Withdrew: Lack of efficacy11
Withdrew: Adverse event42
Withdrew: Physician decision01
Withdrew: Withdrawal by subject25
Withdrew: Protocol deviation20
Withdrew: Site terminated by sponsor01
Withdrew: Study terminated by sponsor01
Withdrew: Death11
Withdrew: Other: unspecified10
Period 2
Participant flow — Period 2
MilestoneSequence A: IgPro20 / IgPro20 / IgPro20Sequence B: Placebo / IgPro20 / IgPro20
Started5655
Treated5655
Completed4038
Not completed1617
Withdrew: Lack of efficacy01
Withdrew: Adverse event01
Withdrew: Physician decision02
Withdrew: Withdrawal by subject55
Withdrew: Lost to follow-up01
Withdrew: Site terminated by sponsor13
Withdrew: Study terminated by sponsor83
Withdrew: Death10
Withdrew: Other: unspecified11
Period 3
Participant flow — Period 3
MilestoneSequence A: IgPro20 / IgPro20 / IgPro20Sequence B: Placebo / IgPro20 / IgPro20
Started3634
Treated3634
Completed1112
Not completed2522
Withdrew: Site terminated by sponsor12
Withdrew: Study terminated by sponsor2418
Withdrew: Missing02

Outcome measures

PrimaryResponder Rate

A responder was defined as a participant with a TIS \>= 20 points at Week 25 and at least 1 of the previous scheduled visits (Week 17 or 21), who completes 24 weeks of randomized IMP treatment without the use of rescue corticosteroid treatment. The TIS was a sum response criterion which incorporates 6 weighted international myositis assessment and clinical studies (IMACS) core set measures (CSMs) including Physician and Patient Global Disease Activity (PGA), Manual Muscle Testing-8 (MMT-8), Health Assessment Questionnaire, Muscle Enzyme, and Extramuscular Global Activity (EGA). Thresholds for minimal, moderate, and major improvement were \>= 20, \>= 40, and \>= 60 points, respectively on the TIS. Percentage of responders at Week 25 based on TIS are reported here. Multiple imputation (MI) was used to impute missing values for participants who discontinued due to the military activities in Ukraine.

Time frame:
At Week 25
Reported as:
Number · percentage of participants
Responder Rate
percentage of participantsIgPro20Placebo
Responder Rate64.3 (52.56 to 75.99)61.6 (49.52 to 73.74)
Statistical analysis
  • IgPro20 vs Placebo · Regression, Logistic · p = 0.371008 (Threshold of significance at \<= 0.025.) · Odds ratio (or): 1.13 · 95% CI 0.551 to 2.309Rubin's rule applied following MI.
SecondaryMean TIS

The TIS was a sum response criterion which incorporates 6 weighted IMACS CSMs including Physician and PGA, MMT-8, Health Assessment Questionnaire, Muscle Enzyme, and EGA. A total improvement score (range 0 to 100; higher the score, better the condition), determined by summing scores for each CSM, was based on improvement in and relative weight of each CSM. Thresholds for minimal, moderate, and major improvement were \>= 20, \>= 40, and \>= 60 points, respectively on the TIS. Least squares (LS) means were estimated using a mixed model repeated measures (MMRM) including treatment, visit, the interaction between treatment and visit, region, and baseline MMT-8 (\<=142 points vs \>142 points) as fixed effects, participant as a random effect.

Time frame:
At Week 25
Reported as:
Least squares mean · score on a scale
Mean TIS
score on a scaleIgPro20Placebo
Mean TIS32.24 (25.275 to 39.208)30.78 (23.668 to 37.896)
Statistical analysis
  • IgPro20 vs Placebo · MMRM · p = 0.360939 (Descriptive p-value.) · Ls mean difference: 1.46 · 95% CI -6.651 to 9.570
SecondaryMean Changes From Baseline in MMT-8

The MMT-8 was a set of 8 designated muscles which were tested bilaterally (potential score ranging from 0 to 150): 7 biaxial muscles with a potential score 0 to 140 and 1 axial (neck flexors) with a potential score of 0 to 10. Improvement is documented with an increase in score. LS means were estimated using a MMRM including treatment, visit, the interaction between treatment and visit, and region as fixed effects, baseline MMT-8 as a continuous covariate and participant as a random effect.

Time frame:
From Baseline to Week 25
Reported as:
Least squares mean · score on a scale
Mean Changes From Baseline in MMT-8
score on a scaleIgPro20Placebo
Mean Changes From Baseline in MMT-88.9 (4.08 to 13.78)11.3 (4.79 to 17.89)
Statistical analysis
  • IgPro20 vs Placebo · MMRM · p = 0.730994 (Descriptive p-value.) · Ls mean difference: -2.4 · 95% CI -10.15 to 5.33
SecondaryMean Changes From Baseline in Cutaneous Dermatomyositis Disease Area and Severity Index Total Activity Score (CDASI-A)

The CDASI in its modified version 2 (V2) is a validated tool of skin disease activity (3 items) and damage (3 items) assessment. Scores range from 0-100 for activity and from 0-32 for damage. Improvement is documented with a decrease in score. LS means were estimated using a MMRM including treatment, visit, the interaction between treatment and visit, region, and baseline MMT-8 (\<=142 points vs \>142 points) as fixed effects, baseline CDASI-A as a continuous covariate, and participants as a random effect.

Time frame:
From Baseline to Week 25
Reported as:
Least squares mean · score on a scale
Mean Changes From Baseline in Cutaneous Dermatomyositis Disease Area and Severity Index Total Activity Score (CDASI-A)
score on a scaleIgPro20Placebo
Mean Changes From Baseline in Cutaneous Dermatomyositis Disease Area and Severity Index Total Activity Score (CDASI-A)-10.6 (-13.28 to -7.82)-5.3 (-8.29 to -2.28)
Statistical analysis
  • IgPro20 vs Placebo · MMRM · p = 0.001647 (Descriptive p-value.) · Ls mean difference: -5.3 · 95% CI -8.72 to -1.82
SecondaryPercentage of Participants Who Are Able to Reduce the Oral Corticosteroid Dose by >= 25%

Reduction in corticosteroid dose.

Time frame:
At Week 25
Reported as:
Number · percentage of participants
Percentage of Participants Who Are Able to Reduce the Oral Corticosteroid Dose by >= 25%
percentage of participantsIgPro20Placebo
Percentage of Participants Who Are Able to Reduce the Oral Corticosteroid Dose by >= 25%23.2 (12.89 to 33.45)20.2 (10.39 to 30.04)
Statistical analysis
  • IgPro20 vs Placebo · Regression, Logistic · p = 0.335347 (Descriptive p-value.) · Odds ratio (or): 1.20 · 95% CI 0.520 to 2.766Rubin's rule for combination applied following MI.
SecondaryPeriod 1: Mean TIS at Each Visit

The TIS was a sum response criterion which incorporates 6 weighted IMACS CSMs including Physician and PGA, MMT-8, Health Assessment Questionnaire, Muscle Enzyme, and EGA. A total improvement score (range 0 to 100), determined by summing scores for each CSM, was based on improvement in and relative weight of each CSM. Thresholds for minimal, moderate, and major improvement were \>= 20, \>= 40, and \>= 60 points on the TIS.

Time frame:
At Week 5, 9, 13, 17, 21, and 25
Reported as:
Mean · score on a scale
Period 1: Mean TIS at Each Visit
score on a scaleIgPro20Placebo
Week 523.22 ± 16.38720.97 ± 16.684
Week 932.54 ± 18.13226.67 ± 17.924
Week 1337.68 ± 17.26731.68 ± 20.705
Week 1741.00 ± 16.92635.44 ± 21.458
Week 2143.56 ± 17.11236.67 ± 21.882
Week 2540.20 ± 20.09340.21 ± 21.812
SecondaryPeriod 2: Mean TIS at Each Visit

The TIS was a sum response criterion which incorporates 6 weighted IMACS CSMs including Physician and PGA, MMT-8, Health Assessment Questionnaire, Muscle Enzyme, and EGA. A total improvement score (range 0 to 100), determined by summing scores for each CSM, was based on improvement in and relative weight of each CSM. Thresholds for minimal, moderate, and major improvement were \>= 20, \>= 40, and \>= 60 points on the TIS.

Time frame:
Week 25, 29, 33, 37, 41, 45, 49, and 53
Reported as:
Mean · score on a scale
Period 2: Mean TIS at Each Visit
score on a scaleSequence A: IgPro20 / IgPro20Sequence B: Placebo / IgPro20
Week 2540.09 ± 19.54738.08 ± 22.658
Week 2945.05 ± 19.93142.74 ± 20.057
Week 3344.66 ± 19.34646.23 ± 18.258
Week 3747.81 ± 18.80548.49 ± 17.071
Week 4150.49 ± 18.25551.68 ± 15.943
Week 4550.89 ± 19.01852.94 ± 15.078
Week 4951.63 ± 17.84450.51 ± 16.010
Week 5350.32 ± 15.88654.26 ± 15.022
SecondaryPeriod 1: Percentage of Participants Achieving TIS ≥ 20, ≥ 40 and ≥ 60 Points

Participants were considered and reported in more than one category (TIS \>= 20, \>= 40 and \>= 60 Points).

Time frame:
At Week 5, 9, 13, 17, 21, and 25
Reported as:
Number · percentage of participants
Period 1: Percentage of Participants Achieving TIS ≥ 20, ≥ 40 and ≥ 60 Points
percentage of participantsIgPro20Placebo
Week 5: TIS >= 20 Points47.7 (35.15 to 60.46)47.7 (35.15 to 60.46)
Week 5: TIS >= 40 Points16.9 (8.76 to 28.27)15.4 (7.63 to 26.48)
Week 5: TIS >= 60 Points1.5 (0.04 to 8.28)1.5 (0.04 to 8.28)
Week 9: TIS >= 20 Points63.1 (50.20 to 74.72)56.3 (43.28 to 68.63)
Week 9: TIS >= 40 Points32.3 (21.23 to 45.05)26.6 (16.30 to 39.09)
Week 9: TIS >= 60 Points9.2 (3.46 to 19.02)4.7 (0.98 to 13.09)
Week 13: TIS >= 20 Points73.8 (61.46 to 83.97)60.9 (47.93 to 72.90)
Week 13: TIS >= 40 Points36.9 (25.28 to 49.80)31.3 (20.24 to 44.06)
Week 13: TIS >= 60 Points13.8 (6.53 to 24.66)10.9 (4.51 to 21.25)
Week 17: TIS >= 20 Points75.4 (63.13 to 85.23)57.8 (44.82 to 70.06)
Week 17: TIS >= 40 Points44.6 (32.27 to 57.47)34.4 (22.95 to 47.30)
Week 17: TIS >= 60 Points15.4 (7.63 to 26.48)15.6 (7.76 to 26.86)
Week 21: TIS >= 20 Points73.4 (60.91 to 83.70)60.3 (47.20 to 72.43)
Week 21: TIS >= 40 Points53.1 (40.23 to 65.72)33.3 (21.95 to 46.34)
Week 21: TIS >= 60 Points18.8 (10.08 to 30.46)12.7 (5.65 to 23.50)
Week 25: TIS >= 20 Points64.1 (51.10 to 75.68)65.1 (52.03 to 76.66)
Week 25: TIS >= 40 Points45.3 (32.82 to 58.25)39.7 (27.57 to 52.80)
Week 25: TIS >= 60 Points17.2 (8.90 to 28.68)15.9 (7.88 to 27.26)
SecondaryPeriod 2: Percentage of Participants Achieving TIS ≥ 20, ≥ 40 and ≥ 60 Points

Participants were considered and reported in more than one category (TIS \>= 20, \>= 40 and \>= 60 Points).

Time frame:
Week 25, 29, 33, 37, 41, 45, 49, and 53
Reported as:
Number · percentage of participants
Period 2: Percentage of Participants Achieving TIS ≥ 20, ≥ 40 and ≥ 60 Points
percentage of participantsSequence A: IgPro20 / IgPro20Sequence B: Placebo / IgPro20
Week 25: TIS >= 20 Points80.0 (67.03 to 89.57)77.8 (64.40 to 87.96)
Week 25: TIS >= 40 Points56.4 (42.32 to 69.70)48.1 (34.34 to 62.16)
Week 25: TIS >= 60 Points20.0 (10.43 to 32.97)18.5 (9.25 to 31.43)
Week 29: TIS >= 20 Points87.0 (75.10 to 94.63)84.9 (72.41 to 93.25)
Week 29: TIS >= 40 Points64.8 (50.62 to 77.32)54.7 (40.45 to 68.44)
Week 29: TIS >= 60 Points31.5 (19.52 to 45.55)22.6 (12.28 to 36.21)
Week 33: TIS >= 20 Points85.2 (72.88 to 93.38)90.6 (79.34 to 96.87)
Week 33: TIS >= 40 Points57.4 (43.21 to 70.77)64.2 (49.80 to 76.86)
Week 33: TIS >= 60 Points22.2 (12.04 to 35.60)24.5 (13.76 to 38.28)
Week 37: TIS >= 20 Points82.7 (69.67 to 91.77)88.5 (76.56 to 95.65)
Week 37: TIS >= 40 Points57.7 (43.20 to 71.27)67.3 (52.89 to 79.67)
Week 37: TIS >= 60 Points28.8 (17.13 to 43.08)25.0 (14.03 to 38.95)
Week 41: TIS >= 20 Points84.3 (71.41 to 92.98)84.6 (71.92 to 93.12)
Week 41: TIS >= 40 Points64.7 (50.07 to 77.57)73.1 (58.98 to 84.43)
Week 41: TIS >= 60 Points37.3 (24.13 to 51.92)30.8 (18.72 to 45.10)
Week 45: TIS >= 20 Points80.0 (66.28 to 89.97)84.3 (71.41 to 92.98)
Week 45: TIS >= 40 Points64.0 (49.19 to 77.08)66.7 (52.08 to 79.24)
Week 45: TIS >= 60 Points40.0 (26.41 to 54.82)31.4 (19.11 to 45.89)
Week 49: TIS >= 20 Points80.0 (66.28 to 89.97)70.0 (55.39 to 82.14)
Week 49: TIS >= 40 Points68.0 (53.30 to 80.48)58.0 (43.21 to 71.81)
Week 49: TIS >= 60 Points36.0 (22.92 to 50.81)22.0 (11.53 to 35.96)
Week 53: TIS >= 20 Points78.0 (64.04 to 88.47)72.0 (57.51 to 83.77)
Week 53: TIS >= 40 Points56.0 (41.25 to 70.01)66.0 (51.23 to 78.79)
Week 53: TIS >= 60 Points30.0 (17.86 to 44.61)24.0 (13.06 to 38.17)
SecondaryPeriod 1: Time to First Achieving TIS >= 20, >= 40, and >= 60 Points on the TIS

The observation was censored if no improvement was observed before the intake of rescue/increased doses of oral corticosteroids in SP1 or before the end of the period.

Time frame:
Up to Week 25
Reported as:
Median · days
Period 1: Time to First Achieving TIS >= 20, >= 40, and >= 60 Points on the TIS
daysIgPro20Placebo
TIS >= 20 Points31.0 (28.00 to 56.00)32.0 (28.00 to 56.00)
TIS >= 40 Points112.0 (63.00 to 141.00)112.0 (84.00 to 168.00)
TIS >= 60 PointsNA (NA to NA)NA (170.00 to NA)
SecondaryPeriod 1 and 2: Time to First Achieving TIS >= 20, >= 40, and >= 60 Points Improvement on the TIS

The observation was censored if no improvement was observed before the intake of rescue/increased doses of oral corticosteroids in SP1 or before the end of the period.

Time frame:
Up to Week 53
Reported as:
Median · days
Period 1 and 2: Time to First Achieving TIS >= 20, >= 40, and >= 60 Points Improvement on the TIS
daysSequence A: IgPro20 / IgPro20Sequence B: Placebo / IgPro20
TIS >= 20 Points31.0 (28.00 to 56.00)32.0 (28.00 to 56.00)
TIS >= 40 Points112.0 (63.00 to 141.00)137.0 (84.00 to 196.00)
TIS >= 60 Points308.0 (196.00 to NA)336.0 (249.00 to NA)
SecondaryMean Changes From Baseline in Individual CSMs (Except Muscle Enzymes) and CDASI

Individual CSMs included following: Myositis Disease Activity Assessment Tool (MDAAT) Physician global disease activity (PGDA), PGA assessment, MMT-8, health assessment questionnaire-disability index (HAQ-DI), and MDAAT-EGA. Higher values were associated with a better state of health for the MMT-8 (range 0 -150) assessment, while lower values were associated with a better state of health for: MDAAT-PGDA (range 0 -100), PGA (range 0-100), HAQ-DI (range 0-3), MDAAT-EGA (range 0 -100), and CDASI-A (range 0-100).

Time frame:
From Baseline to Week 25
Reported as:
Mean · score on a scale
Mean Changes From Baseline in Individual CSMs (Except Muscle Enzymes) and CDASI
score on a scaleIgPro20Placebo
MMT-8: Week 2510.8 ± 16.7115.2 ± 24.02
MDAAT-PGDA: Week 25-21.2 ± 19.86-21.8 ± 18.64
MDAAT-EGA: Week 25-17.4 ± 22.54-13.9 ± 17.67
PGA: Week 25-13.0 ± 26.52-16.8 ± 20.57
HAQ - DI: Week 25-0.195 ± 0.4627-0.172 ± 0.4801
CDASI-A: Week 25-11.5 ± 10.85-7.9 ± 8.91
SecondaryMean Changes From Week 25 in Individual CSMs (Except Muscle Enzymes) and CDASI

Individual CSMs included following: MDAAT-PGDA, PGA assessment, MMT-8, HAQ-DI, and MDAAT extramacular global assessment. Higher values were associated with a better state of health for the MMT-8 (range 0 -150) assessment, while lower values were associated with a better state of health for: MDAAT-PGDA (range 0 -100), PGA (range 0-100), HAQ-DI (range 0-3), MDAAT-EGA (range 0 -100), and CDASI-A (range 0-100).

Time frame:
From Week 25 to Week 53
Reported as:
Mean · score on a scale
Mean Changes From Week 25 in Individual CSMs (Except Muscle Enzymes) and CDASI
score on a scaleSequence A: IgPro20 / IgPro20Sequence B: Placebo / IgPro20
MMT-8: Week 537.1 ± 11.327.9 ± 13.44
MDAAT-PGDA: Week 53-8.5 ± 17.13-15.5 ± 18.74
MDAAT-EGA: Week 53-0.9 ± 12.38-11.5 ± 18.21
PGA: Week 53-3.3 ± 20.94-9.0 ± 23.87
HAQ - DI: Week 53-0.106 ± 0.2587-0.162 ± 0.4477
CDASI-A: Week 53-0.8 ± 7.52-5.3 ± 9.70
SecondaryPeriod 1: Number of Participants Meeting Definition of Worsening (DOW) at Least Once, Twice, or > Twice

The DOW consists of meeting 1 of the following criteria on 2 consecutive visits at least 2 weeks apart: PGA Assessment Visual Analog Scale (VAS) worsening \>= 2 cm\* and MMT-8 worsening \>= absolute 10%, or EGA worsening \>= 2 cm on the MDAAT VAS, or Any 3 of 6 CSM worsening by \>= absolute 20%. (\*If baseline PGA VAS is 8 to 10, then any worsening on Physician Global VAS was acceptable as long as MMT-8 criterion was met.)

Time frame:
Up to Week 25
Reported as:
Count of participants · Participants
Period 1: Number of Participants Meeting Definition of Worsening (DOW) at Least Once, Twice, or > Twice
ParticipantsIgPro20Placebo
At Least Once23
At Least Twice00
More Than Twice00
SecondaryPeriod 1: Percentage of Participants Meeting DOW at Least Once, Twice, or > Twice

The DOW consists of meeting 1 of the following criteria on 2 consecutive visits at least 2 weeks apart: PGA Assessment VAS worsening \>= 2 cm\* and MMT-8 worsening \>= absolute 10%, or EGA worsening \>= 2 cm on the MDAAT VAS, or Any 3 of 6 CSM worsening by \>= absolute 20%. (\*If baseline PGA VAS is 8 to 10, then any worsening on Physician Global VAS was acceptable as long as MMT-8 criterion was met.)

Time frame:
Up to Week 25
Reported as:
Number · percentage of participants
Period 1: Percentage of Participants Meeting DOW at Least Once, Twice, or > Twice
percentage of participantsIgPro20Placebo
At Least Once3.14.6
At Least Twice00
More Than Twice00
SecondaryPeriod 2: Number of Participants Meeting DOW at Least Once, Twice, or > Twice

The DOW consists of meeting 1 of the following criteria on 2 consecutive visits at least 2 weeks apart: PGA Assessment VAS worsening \>= 2 cm\* and MMT-8 worsening \>= absolute 10%, or EGA worsening \>= 2 cm on the MDAAT VAS, or Any 3 of 6 CSM worsening by \>= absolute 20%. (\*If baseline PGA VAS is 8 to 10, then any worsening on Physician Global VAS was acceptable as long as MMT-8 criterion was met.)

Time frame:
From Week 25 up to Week 53
Reported as:
Count of participants · Participants
Period 2: Number of Participants Meeting DOW at Least Once, Twice, or > Twice
ParticipantsSequence A: IgPro20 / IgPro20Sequence B: Placebo / IgPro20
At Least Once21
At Least Twice00
More Than Twice00
SecondaryPeriod 2: Percentage of Participants Meeting DOW at Least Once, Twice, or > Twice

The DOW consists of meeting 1 of the following criteria on 2 consecutive visits at least 2 weeks apart: PGA Assessment VAS worsening \>= 2 cm\* and MMT-8 worsening \>= absolute 10%, or EGA worsening \>= 2 cm on the MDAAT VAS, or Any 3 of 6 CSM worsening by \>= absolute 20%. (\*If baseline PGA VAS is 8 to 10, then any worsening on Physician Global VAS was acceptable as long as MMT-8 criterion was met.)

Time frame:
From Week 25 up to Week 53
Reported as:
Number · percentage of participants
Period 2: Percentage of Participants Meeting DOW at Least Once, Twice, or > Twice
percentage of participantsSequence A: IgPro20 / IgPro20Sequence B: Placebo / IgPro20
At Least Once3.61.9
At Least Twice00
More Than Twice00
SecondaryTime to Meeting DOW for the First Time

The DOW consists of meeting 1 of the following criteria on 2 consecutive visits at least 2 weeks apart: PGA Assessment VAS worsening \>= 2 cm\* and MMT-8 worsening \>= absolute 10%, or EGA worsening \>= 2 cm on the MDAAT VAS, or Any 3 of 6 CSM worsening by \>= absolute 20%. (\*If baseline PGA VAS is 8 to 10, then any worsening on Physician Global VAS was acceptable as long as MMT-8 criterion was met.) The observation was censored if no DOW was observed before the intake of rescue treatment or before the end of the period.

Time frame:
Up to Week 53
Reported as:
Median · days
Time to Meeting DOW for the First Time
daysSequence A: IgPro20 / IgPro20Sequence B: Placebo / IgPro20
Time to Meeting DOW for the First TimeNA (NA to NA)NA (NA to NA)
SecondaryNumber of Participants Meeting DOW and Receiving Rescue Steroid Treatment

The DOW consists of meeting 1 of the following criteria on 2 consecutive visits at least 2 weeks apart: PGA Assessment VAS worsening \>= 2 cm\* and MMT-8 worsening \>= absolute 10%, or EGA worsening \>= 2 cm on the MDAAT VAS, or Any 3 of 6 CSM worsening by \>= absolute 20%. (\*If baseline PGA VAS is 8 to 10, then any worsening on Physician Global VAS was acceptable as long as MMT-8 criterion was met.) The Number of participants meeting DOW and who received rescue steroid treatment are reported here.

Time frame:
Up to Week 25
Reported as:
Count of participants · Participants
Number of Participants Meeting DOW and Receiving Rescue Steroid Treatment
ParticipantsIgPro20Placebo
Number of Participants Meeting DOW and Receiving Rescue Steroid Treatment02
SecondaryPercentage of Participants Meeting DOW and Receiving Rescue Steroid Treatment

The DOW consists of meeting 1 of the following criteria on 2 consecutive visits at least 2 weeks apart: PGA Assessment VAS worsening \>= 2 cm\* and MMT-8 worsening \>= absolute 10%, or EGA worsening \>= 2 cm on the MDAAT VAS, or Any 3 of 6 CSM worsening by \>= absolute 20%. (\*If baseline PGA VAS is 8 to 10, then any worsening on Physician Global VAS was acceptable as long as MMT-8 criterion was met.) The percentage of participants meeting DOW and who received rescue steroid treatment are reported here.

Time frame:
Up to Week 25
Reported as:
Number · percentage of participants
Percentage of Participants Meeting DOW and Receiving Rescue Steroid Treatment
percentage of participantsIgPro20Placebo
Percentage of Participants Meeting DOW and Receiving Rescue Steroid Treatment03.1
SecondaryNumber of Participants Who Start Oral Corticosteroid Dose Taper
Time frame:
Up to Week 25
Reported as:
Count of participants · Participants
Number of Participants Who Start Oral Corticosteroid Dose Taper
ParticipantsIgPro20Placebo
Number of Participants Who Start Oral Corticosteroid Dose Taper1919
SecondaryPercentage of Participants Who Start Oral Corticosteroid Dose Taper
Time frame:
Up to Week 25
Reported as:
Number · percentage of participants
Percentage of Participants Who Start Oral Corticosteroid Dose Taper
percentage of participantsIgPro20Placebo
Percentage of Participants Who Start Oral Corticosteroid Dose Taper41.339.6
SecondaryNumber of Participants Who Are Able to Reduce the Oral Corticosteroid Dose by >= 25%, >= 50%, >= 75%
Time frame:
Up to Week 25 and 52
Reported as:
Count of participants · Participants
Number of Participants Who Are Able to Reduce the Oral Corticosteroid Dose by >= 25%, >= 50%, >= 75%
ParticipantsSequence A: IgPro20 / IgPro20Sequence B: Placebo / IgPro20
Week 25: Reduction >= 25%1614
Week 25: Reduction >= 50%118
Week 25: Reduction >= 75%33
Week 52: Reduction >= 25%1917
Week 52: Reduction >= 50%1714
Week 52: Reduction >= 75%129
SecondaryPercentage of Participants Who Are Able to Reduce the Oral Corticosteroid Dose by >= 25%, >= 50%, >= 75%
Time frame:
Up to Week 25 and 52
Reported as:
Number · percentage of participants
Percentage of Participants Who Are Able to Reduce the Oral Corticosteroid Dose by >= 25%, >= 50%, >= 75%
percentage of participantsSequence A: IgPro20 / IgPro20Sequence B: Placebo / IgPro20
Week 25: Reduction >= 25%40.035.9
Week 25: Reduction >= 50%27.520.5
Week 25: Reduction >= 75%7.57.7
Week 52: Reduction >= 25%47.543.6
Week 52: Reduction >= 50%42.535.9
Week 52: Reduction >= 75%30.023.1
SecondaryPercentage of Participants Receiving Rescue Corticosteroid Treatment
Time frame:
Up to Week 25
Reported as:
Number · percentage of participants
Percentage of Participants Receiving Rescue Corticosteroid Treatment
percentage of participantsIgPro20Placebo
Percentage of Participants Receiving Rescue Corticosteroid Treatment1.59.2
SecondaryPercentage of Participants Whose Rescue Corticosteroid Treatment is Tapered
Time frame:
Up to Week 25
Reported as:
Number · percentage of participants
Percentage of Participants Whose Rescue Corticosteroid Treatment is Tapered
percentage of participantsIgPro20Placebo
Percentage of Participants Whose Rescue Corticosteroid Treatment is Tapered0100.0
SecondaryTime to First Intake of Rescue Corticosteroid Treatment

The observation was censored if no Rescue was observed before the last day of the last week with IMP intake or before the end of the period.

Time frame:
Up to Week 25
Reported as:
Median · days
Time to First Intake of Rescue Corticosteroid Treatment
daysIgPro20Placebo
Time to First Intake of Rescue Corticosteroid TreatmentNA (NA to NA)NA (NA to NA)
SecondaryNumber of Participants Having at Least 1 Level, 2 Levels, and More Than 2 Levels of Improvement From Baseline in Mobility, Self-care, and Usual Activities Domains of EuroQoL 5-Dimension Questionnaire (EQ-5D-5L)

EQ-5D-5L was assessed across 5 levels, with participants selecting the option that best described their health on that day, ranging from "no problems" to "unable to" walk, wash/dress, or perform usual activities. Out of total participants of each arm, only participants having at least 1 Level, 2 Levels, and more than 2 Levels of improvement from baseline in Mobility, Self-care, and Usual Activities Domains of EQ-5D-5L are reported in this outcome measure.

Time frame:
From Baseline to Week 13 and 25
Reported as:
Count of participants · Participants
Number of Participants Having at Least 1 Level, 2 Levels, and More Than 2 Levels of Improvement From Baseline in Mobility, Self-care, and Usual Activities Domains of EuroQoL 5-Dimension Questionnaire (EQ-5D-5L)
ParticipantsIgPro20Placebo
Week 13: Mobility: At least 1 level improvement1615
Week 13: Mobility: At least 2 level improvement10
Week 13: Mobility: More than 2 level improvement00
Week 13: Self-Care: At least 1 level improvement1513
Week 13: Self-Care: At least 2 level improvement22
Week 13: Self-Care: More than 2 level improvement10
Week 13: Usual Activities: At least 1 level improvement1615
Week 13: Usual Activities: At least 2 level improvement13
Week 13: Usual Activities: More than 2 level improvement10
Week 25: Mobility: At least 1 level improvement1014
Week 25: Mobility: At least 2 level improvement53
Week 25: Mobility: More than 2 level improvement00
Week 25: Self-Care: At least 1 level improvement915
Week 25: Self-Care: At least 2 level improvement23
Week 25: Self-Care: More than 2 level improvement20
Week 25: Usual Activities: At least 1 level improvement1513
Week 25: Usual Activities: At least 2 level improvement21
Week 25: Usual Activities: More than 2 level improvement10
SecondaryPercentage of Participants Having at Least 1 Level, 2 Levels, and More Than 2 Levels of Improvement From Baseline in Mobility, Self-care, and Usual Activities Domains of EQ-5D-5L

EQ-5D-5L was assessed across 5 levels, with participants selecting the option that best described their health on that day, ranging from "no problems" to "unable to" walk, wash/dress, or perform usual activities. Out of total participants of each arm, only participants having at least 1 Level, 2 Levels, and more than 2 Levels of improvement from baseline in Mobility, Self-care, and Usual Activities Domains of EQ-5D-5L are reported in this outcome measure.

Time frame:
From Baseline to Week 13 and 25
Reported as:
Number · percentage of participants
Percentage of Participants Having at Least 1 Level, 2 Levels, and More Than 2 Levels of Improvement From Baseline in Mobility, Self-care, and Usual Activities Domains of EQ-5D-5L
percentage of participantsIgPro20Placebo
Week 13: Mobility : At least 1 level improvement28.127.3
Week 13: Mobility : At least 2 level improvement1.80
Week 13: Mobility : More than 2 level improvement00
Week 13: Self-Care : At least 1 level improvement26.323.6
Week 13: Self-Care : At least 2 level improvement3.53.6
Week 13: Self-Care : More than 2 level improvement1.80
Week 13: Usual Activities : At least 1 level improvement28.127.3
Week 13: Usual Activities : At least 2 level improvement1.85.5
Week 13: Usual Activities : More than 2 level improvement1.80
Week 25: Mobility : At least 1 level improvement19.229.2
Week 25: Mobility : At least 2 level improvement9.66.3
Week 25: Mobility : More than 2 level improvement00
Week 25: Self-Care : At least 1 level improvement3.831.3
Week 25: Self-Care : At least 2 level improvement1.96.3
Week 25: Self-Care : More than 2 level improvement1.90
Week 25: Usual Activities : At least 1 level improvement15.829.3
Week 25: Usual Activities : At least 2 level improvement5.35.2
Week 25: Usual Activities : More than 2 level improvement3.50
SecondaryNumber of Participants Having no Reduction in Levels, at Least 1 Level, 2 Levels, and More Than 2 Levels of Improvement From Week 25 in Mobility, Self-care, and Usual Activities Domains of EQ-5D-5L

EQ-5D-5L was assessed across 5 levels, with participants selecting the option that best described their health on that day, ranging from "no problems" to "unable to" walk, wash/dress, or perform usual activities. Out of total participants of each arm, only participants having no reduction, at least 1 Level, 2 Levels, and more than 2 Levels of improvement from baseline in Mobility, Self-care, and Usual Activities Domains of EQ-5D-5L are reported in this outcome measure.

Time frame:
From Week 25 to 41 and 53
Reported as:
Count of participants · Participants
Number of Participants Having no Reduction in Levels, at Least 1 Level, 2 Levels, and More Than 2 Levels of Improvement From Week 25 in Mobility, Self-care, and Usual Activities Domains of EQ-5D-5L
ParticipantsSequence A: IgPro20 / IgPro20Sequence B: Placebo / IgPro20
Week 41: Mobility: No Reduction2928
Week 41: Mobility: At least 1 level improvement108
Week 41: Mobility: At least 2 level improvement10
Week 41: Mobility: More than 2 level improvement01
Week 41: Self-Care: No Reduction3231
Week 41: Self-Care: At least 1 level improvement59
Week 41: Self-Care: At least 2 level improvement31
Week 41: Self-Care: More than 2 level improvement00
Week 41: Usual Activities: No Reduction2331
Week 41: Usual Activities: At least 1 level improvement1310
Week 41: Usual Activities: At least 2 level improvement11
Week 41: Usual Activities: More than 2 level improvement10
Week 53: Mobility: No Reduction2425
Week 53: Mobility: At least 1 level improvement87
Week 53: Mobility: At least 2 level improvement20
Week 53: Mobility: More than 2 level improvement01
Week 53: Self-Care: No Reduction3323
Week 53: Self-Care: At least 1 level improvement211
Week 53: Self-Care: At least 2 level improvement21
Week 53: Self-Care: More than 2 level improvement00
Week 53: Usual Activities: No Reduction2122
Week 53: Usual Activities: At least 1 level improvement1010
Week 53: Usual Activities: At least 2 level improvement32
Week 53: Usual Activities: More than 2 level improvement00
SecondaryPercentage of Participants Having no Reduction in Levels, at Least 1 Level, 2 Levels, and More Than 2 Levels of Improvement From Week 25 in Mobility, Self-care, and Usual Activities Domains of EQ-5D-5L

EQ-5D-5L was assessed across 5 levels, with participants selecting the option that best described their health on that day, ranging from "no problems" to "unable to" walk, wash/dress, or perform usual activities. Out of total participants of each arm, only participants having no reduction, at least 1 Level, 2 Levels, and more than 2 Levels of improvement from baseline in Mobility, Self-care, and Usual Activities Domains of EQ-5D-5L are reported in this outcome measure.

Time frame:
From Week 25 to 41 and 53
Reported as:
Number · percentage of participants
Percentage of Participants Having no Reduction in Levels, at Least 1 Level, 2 Levels, and More Than 2 Levels of Improvement From Week 25 in Mobility, Self-care, and Usual Activities Domains of EQ-5D-5L
percentage of participantsSequence A: IgPro20 / IgPro20Sequence B: Placebo / IgPro20
Week 41: Mobility: No Reduction61.762.2
Week 41: Mobility: At least 1 level improvement21.317.8
Week 41: Mobility: At least 2 level improvement2.12.2
Week 41: Mobility: More than 2 level improvement00
Week 41: Self-Care: No Reduction68.120.0
Week 41: Self-Care: At least 1 level improvement0.620.0
Week 41: Self-Care: At least 2 level improvement6.42.2
Week 41: Self-Care: More than 2 level improvement00
Week 41: Usual Activities: No Reduction48.968.9
Week 41: Usual Activities: At least 1 level improvement27.722.2
Week 41: Usual Activities: At least 2 level improvement2.12.2
Week 41: Usual Activities: More than 2 level improvement2.10
Week 53: Mobility: No Reduction60.067.6
Week 53: Mobility: At least 1 level improvement20.018.9
Week 53: Mobility: At least 2 level improvement5.00
Week 53: Mobility: More than 2 level improvement02.7
Week 53: Self-Care: No Reduction82.562.2
Week 53: Self-Care: At least 1 level improvement5.029.7
Week 53: Self-Care: At least 2 level improvement5.02.7
Week 53: Self-Care: More than 2 level improvement00
Week 53: Usual Activities: No Reduction52.559.5
Week 53: Usual Activities: At least 1 level improvement25.027.0
Week 53: Usual Activities: At least 2 level improvement7.55.4
Week 53: Usual Activities: More than 2 level improvement00
SecondaryPercentage of Participants With Treatment Emergent Adverse Events (TEAEs), Related TEAEs and Serious TEAEs
Time frame:
Up to 5 years
Reported as:
Number · percentage of participants
Percentage of Participants With Treatment Emergent Adverse Events (TEAEs), Related TEAEs and Serious TEAEs
percentage of participantsPeriod 1 Sequence A: IgPro20Period 1 Sequence B: PlaceboPeriod 2 Sequence A: IgPro20 / IgPro20Period 2 Sequence B: Placebo / IgPro20Period 3 Sequence A: IgPro20/ IgPro20 / IgPro20Period 3 Sequence B: Placebo / IgPro20 / IgPro20
TEAEs82.167.269.674.575.076.5
Related TEAEs52.225.417.943.613.920.6
Serious TEAEs4.57.53.65.513.920.6
SecondaryAnnualized Rate of TEAEs, Related TEAEs and Serious TEAEs Per Time at Risk
Time frame:
Up to 5 years
Reported as:
Number · TEAEs per year
Annualized Rate of TEAEs, Related TEAEs and Serious TEAEs Per Time at Risk
TEAEs per yearPeriod 1 Sequence A: IgPro20Period 1 Sequence B: PlaceboPeriod 2 Sequence A: IgPro20 / IgPro20Period 2 Sequence B: Placebo / IgPro20Period 3 Sequence A: IgPro20/ IgPro20 / IgPro20Period 3 Sequence B: Placebo / IgPro20 / IgPro20
TEAEs11.7255.3594.9226.7183.1653.644
Related TEAEs6.3270.9361.3482.1660.1950.240
Serious TEAEs0.2140.2260.0670.1100.1370.288
SecondaryAnnualized Rate of Mild, Moderate, and Severe TEAEs Per Time at Risk
Time frame:
Up to 5 years
Reported as:
Number · TEAEs per year
Annualized Rate of Mild, Moderate, and Severe TEAEs Per Time at Risk
TEAEs per yearPeriod 1 Sequence A: IgPro20Period 1 Sequence B: PlaceboPeriod 2 Sequence A: IgPro20 / IgPro20Period 2 Sequence B: Placebo / IgPro20Period 3 Sequence A: IgPro20/ IgPro20 / IgPro20Period 3 Sequence B: Placebo / IgPro20 / IgPro20
Mild9.1514.0354.0114.3322.4422.157
Moderate2.1451.1620.8432.2390.6061.390
Severe0.3930.1610.0670.1100.1170.096

Adverse events

Collected over Up to 5 years. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Period 1 Sequence A: IgPro201/67 (1.5%)3/67 (4.5%)41/67 (61.2%)
Period 1 Sequence B: Placebo1/67 (1.5%)5/67 (7.5%)33/67 (49.3%)
Period 2 Sequence A: IgPro20 / IgPro201/56 (1.8%)2/56 (3.6%)25/56 (44.6%)
Period 2 Sequence B: Placebo / IgPro200/55 (0%)3/55 (5.5%)33/55 (60%)
Period 3 Sequence A: IgPro20/ IgPro20 / IgPro200/36 (0%)5/36 (13.9%)21/36 (58.3%)
Period 3 Sequence B: Placebo / IgPro20 / IgPro201/34 (2.9%)7/34 (20.6%)17/34 (50%)
Most frequent serious events
Showing 10 of 29
Most frequent serious events
EventPeriod 1 Sequence A: IgPro20Period 1 Sequence B: PlaceboPeriod 2 Sequence A: IgPro20 / IgPro20Period 2 Sequence B: Placebo / IgPro20Period 3 Sequence A: IgPro20/ IgPro20 / IgPro20Period 3 Sequence B: Placebo / IgPro20 / IgPro20
COVID-19Infections and infestations1/670/670/560/550/362/34
COVID-19 pneumoniaInfections and infestations1/672/670/560/550/360/34
PneumoniaInfections and infestations1/670/670/560/550/361/34
Urinary tract infectionInfections and infestations1/670/670/560/550/361/34
CystitisInfections and infestations0/670/670/560/550/361/34
ArthritisMusculoskeletal and connective tissue disorders0/670/670/560/550/361/34
DermatomyositisMusculoskeletal and connective tissue disorders0/670/670/560/550/361/34
Sudden deathGeneral disorders0/670/670/560/550/361/34
Mueller's mixed tumourNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/670/670/560/550/361/34
SyncopeNervous system disorders0/670/670/560/550/361/34
Most frequent other events
Showing 10 of 34
Most frequent other events
EventPeriod 1 Sequence A: IgPro20Period 1 Sequence B: PlaceboPeriod 2 Sequence A: IgPro20 / IgPro20Period 2 Sequence B: Placebo / IgPro20Period 3 Sequence A: IgPro20/ IgPro20 / IgPro20Period 3 Sequence B: Placebo / IgPro20 / IgPro20
COVID-19Infections and infestations5/674/676/564/5513/368/34
NasopharyngitisInfections and infestations2/673/672/565/558/366/34
Infusion site erythemaGeneral disorders12/674/671/5610/550/360/34
HeadacheNervous system disorders12/673/673/563/554/360/34
Urinary tract infectionInfections and infestations1/672/670/562/552/364/34
Infusion site painGeneral disorders4/671/671/565/551/360/34
NauseaGastrointestinal disorders6/674/670/561/552/360/34
Infusion site swellingGeneral disorders6/671/670/563/550/360/34
DiarrhoeaGastrointestinal disorders3/674/675/563/552/363/34
HypercholesterolaemiaMetabolism and nutrition disorders0/670/670/560/551/363/34

Baseline characteristics

Analysis was performed on the safety (SAF) analysis set. The SAF analysis set comprised all participants who were randomized and received any amount of randomized investigational medicinal product (IMP) and were based on the actual treatment sequence received. Here, baseline characteristics are reported for Period 1, as participants from this cohort were selected to proceed to Periods 2 and 3.

Age, Continuous
Age, Continuous(years)IgPro20PlaceboTotal
Mean51.5 ± 15.8649.1 ± 14.0250.3 ± 14.96
Sex: Female, Male
Sex: Female, Male(Participants)IgPro20PlaceboTotal
Female475198
Male201636
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)IgPro20PlaceboTotal
Hispanic or Latino141529
Not Hispanic or Latino5149100
Unknown or Not Reported235
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)IgPro20PlaceboTotal
Race — American Indian or Alaska Native000
Race — Asian101020
Race — Black or African American314
Race — Native Hawaiian or Other Pacific Islander000
Race — White485098
Race — Other6612
08

Study locations

76 sites
  • 8401117 - Arizona Arthritis & Rheumatology Research
    Glendale, Arizona 85306, United States
  • 8401199 - Neuromuscular Research Center
    Phoenix, Arizona 85028, United States
  • 8401129 - UCLA - Rheumatology Los Angeles
    Los Angeles, California 90095, United States
  • 8401473 - RecioMed Clinical Research Network, Inc.
    Boynton Beach, Florida 33472, United States
  • 8401160 - Center For Rheumatology
    Fort Lauderdale, Florida 33334, United States
  • 8401132 - Omega Research Maitland
    Orlando, Florida 32810, United States
  • 8401107 - Morsani Center for Advanced Health Care (CAHC)
    Tampa, Florida 33616, United States
  • 8401152 - The University of Kansas Medical Center
    Fairway, Kansas 66205, United States
  • 8401476 - DS Research
    Louisville, Kentucky 40241, United States
  • 8401487 - Ohio State University
    Columbus, Ohio 43210, United States
  • 8401486 - Oregon Health and Science University
    Portland, Oregon 97239, United States
  • 8401210 - University of Pennsylvania
    Philadelphia, Pennsylvania 19104, United States
  • 8401151 - Biomedical Science Tower
    Pittsburgh, Pennsylvania 15261, United States
  • 8401474 - West Tennessee Research Institute, LLC
    Jackson, Tennessee 38305, United States
  • 8401115 - The University of Texas Medical School at Houston
    Houston, Texas 77030, United States
  • 0320083 - Hospital Italiano de Buenos Aires
    Ciudad Autónoma Buenos Aires, Buenos Aires C1181ACH, Argentina
  • 0320084 - DIM Clinica Privada
    Buenos Aires, B1704ETD, Argentina
  • 0320081 - Fundacion Respirar
    Buenos Aires, C1426ABP, Argentina
  • 0320077 - Centro Medico Privado de Reumatolgia
    San Miguel de Tucumán, T4000, Argentina
  • 0560050 - Ghent Universit Hospital (UZ Gent)
    Ghent, 9000, Belgium
  • 0560048 - Universitair Ziekenhuis (UZ) Leuven
    Leuven, 3000, Belgium
  • 0560056 - Universitair Ziekenhuis Leuven
    Leuven, 3000, Belgium
  • 0560049 - CHU de Liège - Sart Tilman
    Liège, 4000, Belgium
  • 2500146 - CHU De Dijon Hopital Du Bocage
    Dijon, 21079, France
  • 2500188 - Centre Hospitalier Regional Universitaire de Lille
    Lille, 59037, France
  • 2500133 - CHU - Hospital de la Timone
    Marseille, 13385, France
  • 2500135 - CHU Nice-Hopital Archet I
    Nice, 06202, France
  • 2500132 - Hopital Pitie-Salpetriere
    Paris, 75013, France
  • 2500144 - Hopitaux Universitaire de Strasbourg
    Strasbourg, 67098, France
  • 2760203 - Charité
    Berlin, 10117, Germany
  • 2760211 - Charité - Universitätsmedizin Berlin
    Berlin, 10117, Germany
  • 2760199 - University Hospital Köln
    Cologne, 50937, Germany
  • 2760271 - Universitatsklinikum Carl Gustav Carus TU Dresden
    Dresden, 01307, Germany
  • 2760273 - Hautklinik des Uni-Klinikums Erlangen
    Erlangen, 91504, Germany
  • 2760036 - University Medicine Göttingen
    Göttingen, 37075, Germany
  • 2760201 - Medizinische Hochschule Hannover (MHH)
    Hanover, 30625, Germany
  • 2760210 - University of Münster
    Münster, 48149, Germany
  • 2760212 - University Hospital Of Tuebingen
    Tübingen, 72076, Germany
  • 2760268 - University of Ulm
    Ulm, 89081, Germany
  • 3480048 - University of Debrecen
    Debrecen, 4032, Hungary
  • 3800133 - Universita degli Studi Di Brescia - Azienda Ospedaliera Spedali Civili di Brescia
    Brescia, 25123, Italy
  • 3800132 - Universitaria Vittorio Emanuele
    Catania, 95124, Italy
  • 3800139 - Universita degli Studi Firenze
    Florence, 50134, Italy
  • 3800134 - Azienda Ospedaliero Universitaria Pisana
    Pisa, 56124, Italy
  • 3920096 - Chukyo Hospital
    Nagoya, Aichi-ken 457-8510, Japan
  • 3920090 - University Of Fukui Hospital
    Yoshida-Gun, Fukui 910-1193, Japan
  • 3920088 - Gunma University Hospital
    Maebashi, Gunma 371-6511, Japan
  • 3920089 - Hokkaido University Hospital
    Sapporo, Hokkaido 060-8648, Japan
  • 3920086 - St. Marianna University Hospital
    Kawasaki, Kanagawa 216-8511, Japan
  • 3920125 - Tokyo Medical And Dental University Medical Hospital
    Bunkyo, Tokyo 113-8519, Japan
  • 3920091 - Nippon Medical School Hospital
    Bunkyō-Ku, Tokyo 113-8603, Japan
  • 3920097 - Tokyo Women's Medical University Hospital
    Shinjuku-Ku, Tokyo 162-8666, Japan
  • 3920087 - Wakayama Medical University Hospital
    Wakayama, 641-8509, Japan
  • 3920035 - Yamaguchi University Hospital
    Yamaguchi, 755-8505, Japan
  • 4840081 - Centro Integral en Reumatologia, SA de CV
    Guadalajara, Jalisco 44160, Mexico
  • 4840082 - CINTRE, Centro de Investigacion y Tratamiento Reumatologico S.C.
    Mexico City, Mexico City 11850, Mexico
  • 4840084 - Centro de Alta Especialidad en Reumatologia e Investigacion del Potosí, S.C.
    San Luis Potosí City, 78213, Mexico
  • 6160104 - Zespol Poradni Specjalistycznych REUMED, ONYKSOWA Filia nr 2
    Lublin, 20-582, Poland
  • 6160117 - MedicalConcierge Centrum Medyczne
    Warsaw, 02-798, Poland
  • 6430124 - ORIS Firm Limited Liability Company
    Moscow, 117321, Russia
  • 6430122 - City Clinical Hospital No. 5
    Nizhny Novgorod, 603005, Russia
  • 6430125 - Medical Centre-Healthy Family
    Novosibirsk, 630099, Russia
  • 6430120 - St. Petersburg City Rheumatological Hospital 25
    Saint Petersburg, 190068, Russia
  • 6430123 - Yaroslavl Oblast Clinical Hospital
    Yaroslavl, 150007, Russia
  • 7240086 - Complejo Hospitalario Universitario A Coruña
    A Coruña, 15006, Spain
  • 7240011 - Hospital Universitario Valle de Hebron
    Barcelona, 08035, Spain
  • 7240112 - Hospital Clinic Barcelona
    Barcelona, 08036, Spain
  • 7560033 - University Hospital Bern Inselspital
    Bern, 3010, Switzerland
  • 7560028 - Kantonsspital St. Gallen
    Sankt Gallen, 9007, Switzerland
  • 8040053 - Cherkassy Regional Hospital
    Cherkasy, 18009, Ukraine
  • 8040055 - Mechnikov Institute of Microbiology and Immunology
    Kharkiv, 61029, Ukraine
  • 8040057 - Khmelnitskiy Regional Hospital
    Khmelnytskyi, 29000, Ukraine
  • 8040058 - State Institution National Scientific Center Strazhesko
    Kiev, 03151, Ukraine
  • 8040052 - Institute of Rheumatology
    Kyiv, 02081, Ukraine
  • 8040051 - Kyiv Railway Clinical Hospital No.2
    Kyiv, 03049, Ukraine
  • 8040054 - Modern Clinic LLC
    Zaporizhia, 69005, Ukraine
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — CSL will consider requests to share Individual Patient Data (IPD) from systematic review groups or bona-fide researchers. For information on the process and requirements for submitting a voluntary data sharing request for IPD, please contact CSL at clinicaltrials@cslbehring.com. Applicable country specific privacy and other laws and regulations will be considered and may prevent sharing of IPD. If the request is approved and the researcher has executed an appropriate data sharing agreement, IPD that has been appropriately anonymized will be available.

Supporting information: Study protocol, Statistical analysis plan

Time frame: IPD requests may be submitted to CSL no earlier than 12 months after publication of the results of this study via an article made available on a public website.

Access criteria: Requests may only be made by systematic review groups or bona-fide researchers whose proposed use of the IPD is non-commercial in nature and has been approved by an internal review committee. An IPD request will not be considered by CSL unless the proposed research question seeks to answer a significant and unknown medical science or patient care question as determined by CSL's internal review committee. The requesting party must execute an appropriate data sharing agreement before IPD will be made available.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2019 to primary completion in Dec 2024, 61 months.

Results were first posted in Dec 2025, 1 year after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 1, 2019
First posted
Aug 5, 2019
StartActual
Oct 21, 2019
Primary completionActual
Dec 2, 2024
CompletionActual
Dec 2, 2024
Results first posted
Dec 9, 2025
Last update
Dec 9, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 9, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04044690
Lead sponsor
CSL Behring
Responsible party
Sponsor
First posted
Aug 5, 2019
Start date
Oct 21, 2019
Primary completion
Dec 2, 2024
Completion
Dec 2, 2024
Results posted
Dec 9, 2025
Last update
Dec 9, 2025

Study contacts

Study Director
study director · CSL Behring

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Nov 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Immunoglobulins, Intravenous

Start the discussion